| abstract |
The present invention relates to phenethanolamine derivatives of formula (I), wherein R1 represents an aryl group optionally substituted by one or more substituents selected from halogen, hydroxy, C¿1-6?alkoxy, C1-6alkyl, nitro, cyano, hydroxymethyl and trifluoromethyl; R?2¿ represents hydrogen or C¿1-6?alkyl; R?3¿ represents a group (A) where the aromatic ring may be optionally substituted by up to four substituents selected from C¿1-6?alkyl, halogen, trifluoromethyl, and C1-6alkoxy; R?4¿ represents hydrogen, or C¿1-6?alkyl; R?5¿ represents CO¿2R?8, C1-6alkylCO2R?16, CONR9R10¿, NHCONR?11R12, SO¿2NHR13, P(O)(OR14)2, SO3H, C1-6alkylSO3H, NHSO2R?15, NHCOR17¿ or tetrazol-5-yl; R?6 and R7¿ independently represent hydrogen, C¿1-6?alkyl, trifluoromethyl, CN, OH, CO2R?18, CH¿2CO2R?19, or R6 and R7¿ form a 5-6 membered cycloalkyl ring; R8 represents hydrogen, or C¿1-6?alkyl; R?9¿ represents hydrogen, C¿1-6?alkyl, or C1-6alkylOR?20; R10, R11, R12, R14-R16, and R18-R20¿ each independently represent hydrogen, or C¿1-6?alkyl; R?13¿ represents C¿1-6?alkyl or trifluoromethyl; R?17¿ represents C¿1-6?alkyl or trifluoromethyl; with the proviso that when R?6 and R7¿ are both hydrogen, R8 is other than hydrogen; and physiologically acceptable derivatives thereof; to processes for their preparation; and their use in the treatment of conditions susceptible of amelioration by an atypical beta-adrenoceptor agonist. |